Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cathinone derivatives

MDPHP

C17H23NO3 CAS 776994-64-0 Analytical reference material — not for human consumption
MDPHP, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
MDPHP
IUPAC name
1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylhexan-1-one
Parent CAS number (reference)
776994-64-0
Molecular formula
C17H23NO3
Molecular weight
289.4 g/mol
InChIKey
OBLFRFGUZZRECT-UHFFFAOYSA-N
PubChem
CID 119057580
Source
PubChem
Verified synonyms & catalog abbreviations
Methylenedioxypyrrolidinohexiophenone 3 4-MDPHP

Verified Neurochemical & Toxicological Intelligence

MDPHP (3',4'-Methylenedioxy-alpha-pyrrolidinohexiophenone)

Potent Stimulant (High-Affinity Selective NDRI) Substituted cathinone / Pyrovalerone (3,4-methylenedioxy-pyrrolidinophenone)
Verified PubChem & CAS Identity C17H23NO3 · CAS 776994-64-0 · CID 119057580
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 289.38 g/mol
Peer-Reviewed & Agency Citations 4 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

Potent norepinephrine-dopamine reuptake inhibitor (NDRI) and six-carbon homologue of MDPV (and 3,4-methylenedioxy analogue of alpha-PHP). Despite its benzodioxole ring, the bulky pyrrolidine moiety abolishes serotonin affinity: IC50 values measure 8.4–50 nM at DAT and 60–935 nM at NET versus 9,000 nM at SERT. Thus MDPHP lacks MDMA-like serotonergic empathy (even though it cross-reacts on hospital ecstasy immunoassays) and instead delivers intense catecholaminergic stimulation.

Biotransformation & Active Metabolites

Human HRMS studies confirm principal alpha-pyrrolidinophenone metabolic pathways (demethylenation, keto reduction, pyrrolidine ring oxidation). Published clinical toxicology confirms transplacental transfer with fetal blood levels exceeding maternal blood (76 ng/mL vs. 16 ng/mL) in a documented fetal demise case.

Temporal Pharmacokinetics

Powerful, long-tail pyrovalerone stimulant combining intense mental drive, task fixation, ego inflation, and strong libido boost with heavy cardiovascular strain.

  1. Onset 30–60 minutes oral (5–15 minutes mucosal)
  2. Peak Window 1.5–3 hours oral (45–90 minutes mucosal)
  3. Total Window 3–6 hours oral (2–4 hours mucosal)
  4. Residual / Half-Life 2–16 hours oral (2–36 hours mucosal, with post-binge fatigue lasting 1–4 days); human plasma half-life is unverified.

Active at single-digit to low-double-digit milligrams (TripSit common oral 20–35 mg, KnowDrugs 20–40 mg; mucosal 10–20 mg), with batch potency varying widely. Long-lasting after-effects (2–16 hours oral, up to 36 hours mucosal) mean repeated exposure rapidly causes multi-day sleep deprivation, severe paranoid psychosis, rhabdomyolysis, and documented single-substance fatalities.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
3–5 mg (tentative estimate below 5 mg light floor; mucosal: 2–5 mg)
Cognitive & Sensory

Crisp wakefulness, heightened vigilance, and subtle mood elevation.

Somatic & Autonomic

Mild heart-rate increase and appetite suppression.

Light
10–20 mg (KnowDrugs 5–20 mg; mucosal: 5–10 mg)
Cognitive & Sensory

Strong focus intensification, motivation boost, confidence, and energetic sociability.

Somatic & Autonomic

Noticeable pulse and blood-pressure rise, dry mouth, and light muscle tension.

Common Reference
20–35 mg (KnowDrugs 20–40 mg; mucosal: 10–20 mg)
Cognitive & Sensory

Intense dopaminergic mood elevation, pronounced libido increase, ego inflation, rapid thought streams, and urge to redose.

Somatic & Autonomic

Significant hypertension and tachycardia, vasoconstriction, jaw clenching, frequent urination, and temporary erectile dysfunction.

Strong
35–60 mg (mucosal: 20+ mg)
Cognitive & Sensory

Thought disorganization, hyper-vigilant anxiety, compulsive fixation, mania, and emerging paranoia.

Somatic & Autonomic

Heavy cardiac pounding, chest pain, muscle cramps, tremors, headaches, and prolonged 16–36 hour insomnia.

Heavy / Toxic Zone
60+ mg (or binge repeated exposure)
Cognitive & Sensory

Severe paranoid psychosis, hallucinations, delusions, and multi-day exhaustion.

Somatic & Autonomic

Rhabdomyolysis, severe hypertension and tachycardia, chest pain, seizures, and documented fatal single-drug intoxication.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Nanomolar DAT blockade (IC50 8.4–50 nM) combined with MAO inhibition causes catastrophic hypertensive crisis and cardiac arrest.

25x-NBOMe / 25x-NBOH (documented severe clinical 25E-NBOH + MDPHP co-intoxication)

Published ICU toxicology confirms severe vasoconstriction, serotonin/sympathomimetic crisis, seizures, and risk of heart failure.

Other stimulants (Cocaine, alpha-PVP, alpha-PHP, alpha-PiHP, NEP, Hexen, MDMA, Amphetamines) and Tramadol

Extreme additive myocardial strain, rhabdomyolysis, hypertension, and convulsions.

Elevated Hazard — Avoid

Alcohol, Opioids, and GHB/GBL

Masks depressant respiratory risk during peak while worsening cardiac toxicity; strictly contraindicated in pregnancy due to confirmed placental transfer and fetal demise.

Dissociatives (PCP analogues) and Psychedelics

High risk of acute manic psychosis, delusions, and erratic behavioral toxicity.

Caution / Receptor Attenuation

Cannabis

Frequently triggers severe paranoia, hallucinations, and tachycardia during MDPHP's long offset.

Caffeine

Intensifies restlessness, muscle tension, and blood-pressure spikes.

Structural Isomer & Sibling Comparison

MDPHP is the 3,4-methylenedioxy analogue of alpha-PHP and one-carbon homologue of MDPV. Compared to alpha-PVP and alpha-PHP, MDPHP has slightly higher milligram brackets (common oral 20–35 mg vs. 10–25 mg) and milder peak intensity than MDPV, yet shares their negligible-serotonin NDRI profile, prolonged 16–36 hour insomnia tail, and high psychosis risk on repeated exposure. Unlike eutylone (which also carries a benzodioxole ring), MDPHP lacks partial SERT release.

Physicochemical Stability & Storage

Physical Form: White to off-white crystalline solid (hydrochloride salt, MW 325.8 g/mol) or fine tan/beige powder. · HCl salt is soluble in PBS (pH 7.2, ~10 mg/mL), ethanol (~1 mg/mL), methanol (~1 mg/mL), and DMSO (~0.5 mg/mL).

Store sealed in an airtight, light-protected container in a cool, dry place.

Cross-Tolerance & Dependence Profile

Very high psychological dependence and binge-addiction liability; cross-tolerant with all dopaminergic stimulants (alpha-PVP, alpha-PHP, alpha-PiHP, NEP, cocaine). Post-binge crash involves 1–4 days of physical fatigue, thought disorganization, back/muscle aches, and vivid nightmares.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

NET Norepinephrine transporter

NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.

SERT Serotonin transporter

SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.

SNDRA / NDRI Releaser or reuptake blocker

An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

5-HT ↑↑ Serotonergic Overload (Serotonin Toxicity)

A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.

HR / Naczynia Vasoconstriction & Cardiovascular Load

Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.

Comprehensive Analytical & Toxicological Monograph

MDPHP (3',4'-methylenedioxy-alpha-pyrrolidinohexiophenone; 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one; freebase CAS 776994-64-0, hydrochloride CAS 24622-61-5, PubChem CID 119057580) is a pyrovalerone-class cathinone stimulant supplied as pure analytical powder or crystalline solid (C17H23NO3, 289.38 g/mol). Although MDPHP carries a 3,4-methylenedioxy ring—and can cause false-positive ecstasy immunoassay results in clinical laboratories—its pyrrolidine ring abolishes serotonin transporter affinity (SERT IC50 = 9,000 nM) while conferring potent norepinephrine-dopamine reuptake inhibition (DAT IC50 = 8.4–50 nM, NET IC50 = 60–935 nM). Consequently, MDPHP produces no MDMA-like empathy and instead delivers strong, sustained catecholaminergic stimulation, task fixation, ego inflation, and heightened libido. Calibrated milligram measurement is mandatory: tentative TripSit and KnowDrugs oral brackets place threshold effects around 3–5 mg, light focus and energy at 10–20 mg (mucosal 5–10 mg), common strong stimulation at 20–35 mg (mucosal 10–20 mg), intense cardiovascular and anxiogenic load at 35–60 mg, and heavy exposures above 60 mg or binge repeated exposure carry documented risks of rhabdomyolysis, acute paranoid psychosis, chest pain, and fatal single-substance intoxication. Oral effects start in 30–60 minutes and last 3–6 hours, followed by a protracted 2–16 hour oral (up to 36 hour mucosal) after-effect window that makes repeated exposure particularly hazardous. Compared to alpha-PVP and alpha-PHP, MDPHP uses slightly higher milligram amounts (20–35 mg vs. 10–25 mg) while remaining stronger and longer-lingering than NEP or Hexen. Never combine MDPHP with MAOIs, 25x-NBOMe/NBOH, cocaine, other cathinones, tramadol, or PCP-type dissociatives, and strictly avoid during pregnancy due to confirmed transplacental fetal demise.

Chemical Architecture & Structural Profile

MDPHP (1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C17H23NO3 and a molar mass of 289.4 g/mol. The parent molecule is indexed under CAS registry number 776994-64-0 and in the NCBI PubChem database as CID 119057580 (Standard InChIKey: OBLFRFGUZZRECT-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), MDPHP is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations